Hrain Biotechnology Co., Ltd.

Hrain Biotechnology Co., Ltd. (恒润达生) is an innovative biopharmaceutical company founded in Shanghai in July 2015, focused on the R&D and production of breakthrough immune cell therapy drugs, mainly targeting malignant hematologic diseases and solid tumors. The company leads with self-developed CAR-T cell therapy products while also developing CAR-NK technology. It states it has one approved Class I innovative biological product and is simultaneously advancing registration clinical filings for four Class I innovative biological products (CAR-T cell therapy products). Its product pipeline covers CAR-T and CAR-NK cell therapies, and its manufacturing base is located in Shanghai Jinshan Industrial Park with GMP-compliant virus and CAR-T cell production.

Hrain Biotechnology Co., Ltd. (恒润达生) was founded in Shanghai in July 2015. It describes itself as an innovative biopharmaceutical company focused on the R&D and production of breakthrough immune cell therapy drugs, mainly targeting malignant hematologic diseases and solid tumors. The company leads with self-developed CAR-T cell therapy products while also developing CAR-NK and other internationally advanced technologies, aiming to develop safe, effective, cost-controllable immune cell therapy products that benefit more patients. It states it has one approved Class I innovative biological product and is simultaneously advancing registration clinical filings for four Class I innovative biological products (CAR-T cell therapy products). The company has built a complete self-developed technology platform supporting the full process of cell therapy product R&D and production, covering antibody screening and validation, CAR structure design, viral vector large-scale production, cell therapy product large-scale production, and quality inspection and release platforms. Its manufacturing base is located in Shanghai Jinshan Industrial Park, with GMP-compliant virus and CAR-T cell production. Its product pipeline includes CAR-T and CAR-NK cell therapies, and it states it has laid out dozens of pipeline candidates. Its flagship product is 雷尼基奥仑赛注射液 (brand name 恒凯莱®, English brand name HICARA®), described as China's first fully domestically-produced lymphoma CAR-T drug.

Innovative biopharmaceutical company focused on breakthrough immune cell therapy drugs, aiming to develop safe, effective, cost-controllable cell therapies benefiting more patients.

• CAR-T cell therapy

  CAR-T cell therapy uses genetic engineering technology to express CAR on the surface of T cells; the CAR contains three functional domains: an extracellular domain, a transmembrane domain, and an intracellular domain.

• CAR-NK cell therapy

  CAR-NK cell therapy (chimeric antigen receptor NK cell therapy) involves introducing CAR into NK cells to give them the ability to specifically recognize and kill tumor cells.

• 雷尼基奥仑赛注射液 (恒凯莱® / HICARA®)

  Described as China's first fully domestically-produced lymphoma CAR-T drug; included in the 2026 CSCO lymphoma guidelines with a Class II recommendation for R/R DLBCL.

1. 1上海恒润达生生物科技股份有限公司dashengbio.com
2. 2产品管线-上海恒润达生生物科技股份有限公司dashengbio.com
3. 3公司简介-上海恒润达生生物科技股份有限公司dashengbio.com
4. 4公司简介-上海恒润达生生物科技股份有限公司dashengbio.com